Standardized Method to Functionalize Plasma-Extracellular Vesicles via Copper-Free Click Chemistry for Targeted Drug Delivery Strategies.

click chemistry extracellular vesicles surface functionalization tumor cells

Journal

ACS applied bio materials
ISSN: 2576-6422
Titre abrégé: ACS Appl Bio Mater
Pays: United States
ID NLM: 101729147

Informations de publication

Date de publication:
16 Jan 2024
Historique:
medline: 16 1 2024
pubmed: 16 1 2024
entrez: 16 1 2024
Statut: aheadofprint

Résumé

Extracellular vesicles (EVs) have emerged as potential vehicles for targeted drug delivery and diagnostic applications. However, achieving consistent and reliable functionalization of EV membranes remains a challenge. Copper-catalyzed click chemistry, commonly used for EV surface modification, poses limitations due to cytotoxicity and interference with biological systems. To overcome these limitations, we developed a standardized method for functionalizing an EV membrane via copper-free click chemistry. EVs derived from plasma hold immense potential as diagnostic and therapeutic agents. However, the isolation and functionalization of EVs from such a complex biofluid represent considerable challenges. We compared three different EV isolation methods to obtain an EV suspension with an optimal purity/yield ratio, and we identified sucrose cushion ultracentrifugation (sUC) as the ideal protocol. We then optimized the reaction conditions to successfully functionalize the plasma-EV surface through a copper-free click chemistry strategy with a fluorescently labeled azide, used as a proof-of-principle molecule. Click-EVs maintained their identity, size, and, more importantly, capacity to be efficiently taken up by responder tumor cells. Moreover, once internalized, click EVs partially followed the endosomal recycling route. The optimized reaction conditions and characterization techniques presented in this study offer a foundation for future investigations and applications of functionalized EVs in drug delivery, diagnostics, and therapeutics.

Identifiants

pubmed: 38227342
doi: 10.1021/acsabm.3c00822
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Maria Chiara Ciferri (MC)

Department of Experimental Medicine, University of Genova, Largo Rosanna Benzi 10, Genova 16132, Italy.

Silvia Bruno (S)

Department of Experimental Medicine, University of Genova, Largo Rosanna Benzi 10, Genova 16132, Italy.

Nicole Rosenwasser (N)

Department of Experimental Medicine, University of Genova, Largo Rosanna Benzi 10, Genova 16132, Italy.

Cansu Gorgun (C)

Department of Experimental Medicine, University of Genova, Largo Rosanna Benzi 10, Genova 16132, Italy.

Daniele Reverberi (D)

UO Molecular Pathology, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, Genova 16132, Italy.

Maria Cristina Gagliani (MC)

Department of Experimental Medicine, University of Genova, Largo Rosanna Benzi 10, Genova 16132, Italy.

Katia Cortese (K)

Department of Experimental Medicine, University of Genova, Largo Rosanna Benzi 10, Genova 16132, Italy.

Cristina Grange (C)

Department of Medical Sciences, University of Torino, Via Nizza 52, Torino 10126, Italy.

Benedetta Bussolati (B)

UO Cellular Oncology, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, Genova 16132, Italy.

Rodolfo Quarto (R)

Department of Experimental Medicine, University of Genova, Largo Rosanna Benzi 10, Genova 16132, Italy.
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy.

Roberta Tasso (R)

Department of Experimental Medicine, University of Genova, Largo Rosanna Benzi 10, Genova 16132, Italy.
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy.

Classifications MeSH